VEGFA and age-related macular degeneration: Sixty-one eyes of 61 patients scheduled for anti-VEGF therapy for AMD-associated treatment-naïve type 1 MNV (mean age = 78.7 ± 9.7 years) were included. Table 1 provides an overview of the demographic and clinical characteristics of this study cohort.